Nabriva Therapeutics Statistics
Share Statistics
Nabriva Therapeutics has 3.2M
shares outstanding. The number of shares has increased by -93.8%
in one year.
| Shares Outstanding | 3.2M |
| Shares Change (YoY) | -93.8% |
| Shares Change (QoQ) | -95.15% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 28 |
| FTD / Avg. Volume | 0.2% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.09 and the forward
PE ratio is null.
Nabriva Therapeutics's PEG ratio is
0.
| PE Ratio | -0.09 |
| Forward PE | n/a |
| PS Ratio | 0.14 |
| Forward PS | n/a |
| PB Ratio | 1.54 |
| P/FCF Ratio | -0.14 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Nabriva Therapeutics has an Enterprise Value (EV) of -2.12M.
| EV / Sales | -0.06 |
| EV / EBITDA | 0.04 |
| EV / EBIT | 0.06 |
| EV / FCF | 0.06 |
Financial Position
The company has a current ratio of 1.13,
with a Debt / Equity ratio of 1.59.
| Current Ratio | 1.13 |
| Quick Ratio | 0.78 |
| Debt / Equity | 1.59 |
| Debt / EBITDA | -0.1 |
| Debt / FCF | -0.14 |
| Interest Coverage | -73.31 |
Financial Efficiency
Return on Equity is -1736.56% and Return on Invested Capital is -617.99%.
| Return on Equity | -1736.56% |
| Return on Assets | -180.03% |
| Return on Invested Capital | -617.99% |
| Revenue Per Employee | $914,564.1 |
| Profits Per Employee | $-1,466,282.05 |
| Employee Count | 39 |
| Asset Turnover | 1.12 |
| Inventory Turnover | 2.95 |
Taxes
| Income Tax | 1.57M |
| Effective Tax Rate | -2.82% |
Stock Price Statistics
The stock price has increased by 125.4% in the
last 52 weeks. The beta is 1.55, so Nabriva Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.55 |
| 52-Week Price Change | 125.4% |
| 50-Day Moving Average | 1.28 |
| 200-Day Moving Average | 1.65 |
| Relative Strength Index (RSI) | 34.11 |
| Average Volume (20 Days) | 13,843 |
Income Statement
In the last 12 months, Nabriva Therapeutics had revenue of 35.67M
and earned -57.19M
in profits. Earnings per share was -21.32.
| Revenue | 35.67M |
| Gross Profit | 7.09M |
| Operating Income | -51.17M |
| Net Income | -57.19M |
| EBITDA | -54.7M |
| EBIT | -50.6M |
| Earnings Per Share (EPS) | -21.32 |
Full Income StatementBalance Sheet
The company has 12.41M in cash and 5.22M in
debt, giving a net cash position of 7.19M.
| Cash & Cash Equivalents | 12.41M |
| Total Debt | 5.22M |
| Net Cash | 7.19M |
| Retained Earnings | -652.86M |
| Total Assets | 24.34M |
| Working Capital | -4.3M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -36.71M
and capital expenditures -211K, giving a free cash flow of -36.92M.
| Operating Cash Flow | -36.71M |
| Capital Expenditures | -211K |
| Free Cash Flow | -36.92M |
| FCF Per Share | -13.77 |
Full Cash Flow StatementMargins
Gross margin is 19.87%, with operating and profit margins of -143.47% and -160.33%.
| Gross Margin | 19.87% |
| Operating Margin | -143.47% |
| Pretax Margin | -155.93% |
| Profit Margin | -160.33% |
| EBITDA Margin | -153.36% |
| EBIT Margin | -143.47% |
| FCF Margin | -103.52% |
